Sinovac Biotech (SVA +3.9%) says a new drug application for its proprietary EV71 vaccine has...

|About: Sinovac Biotech, Ltd. (SVA)|By:, SA News Editor

Sinovac Biotech (SVA +3.9%) says a new drug application for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. SVA completed the Phase III clinical trials for the vaccine in March, and top-line data showed approximately a 95% efficacy rate against HFMD caused by enterovirus 71. The Administration plans to conduct an on-site inspection and will submit its opinion to China's Food and Drug Administration for further review and evaluation.